![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
December 3, 2025
November 20, 2025
Posts
#FindingsFriday: ICYMI, the PATINA trial (published in @NEJM) shows that adding palbociclib to maintenance anti-HER2 & endocrine therapy significantly improved PFS in HR+/HER2+ metastatic #BreastCancer: @PrECOGonc @alliance_trials @BCTrialsANZ @_SOLTI
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer | NEJM
Dual anti–human epidermal growth factor receptor 2 (HER2) therapy plus chemotherapy followed by maintenance treatment ...
bit.ly
We just enrolled and randomized our first patient on EA2234, the STOPGAPII trial for patients with #gastric #cancer and peritoneal metastasis.
Refer your eligible patients!
@Senthilsurgonc @eaonc @UMGCCC
EA2234 / STOPGAP II Home Page
EA2234 / STOPGAP II Stomach Cancer Clinical Trial Home Page
Explore this research study for patients with gastric or gastroesophageal cancer that has spread to the abdominal ca...
ecog-acrin.org
#ClinicalTrial MM1OA-EA02, led by @jaltmanmd of @LurieCancer, aims to improve results for older adults with #AcuteMyeloidLeukemia (#AML). Learn more: https://bit.ly/mm1oa-ea02-study #BloodCancer #leukemia
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
37
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
